Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.

Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S.

Nat Chem Biol. 2018 Aug;14(8):768-777. doi: 10.1038/s41589-018-0081-9. Epub 2018 Jun 25.

PMID:
29942081
2.

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.

Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, Thompson W, Smith R, Nederlof M, Bucher E, Kilburn D, Whitman M, Sudar D, Mills GB, Heiser LM, Jonas O, Gray JW, Korkola JE.

Cell Syst. 2018 Mar 28;6(3):329-342.e6. doi: 10.1016/j.cels.2018.02.001. Epub 2018 Mar 14.

3.

CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG.

Cancer Res. 2018 Apr 1;78(7):1657-1671. doi: 10.1158/0008-5472.CAN-17-0915. Epub 2018 Jan 22.

PMID:
29358169
4.

The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations.

Keenan AB, Jenkins SL, Jagodnik KM, Koplev S, He E, Torre D, Wang Z, Dohlman AB, Silverstein MC, Lachmann A, Kuleshov MV, Ma'ayan A, Stathias V, Terryn R, Cooper D, Forlin M, Koleti A, Vidovic D, Chung C, Schürer SC, Vasiliauskas J, Pilarczyk M, Shamsaei B, Fazel M, Ren Y, Niu W, Clark NA, White S, Mahi N, Zhang L, Kouril M, Reichard JF, Sivaganesan S, Medvedovic M, Meller J, Koch RJ, Birtwistle MR, Iyengar R, Sobie EA, Azeloglu EU, Kaye J, Osterloh J, Haston K, Kalra J, Finkbiener S, Li J, Milani P, Adam M, Escalante-Chong R, Sachs K, Lenail A, Ramamoorthy D, Fraenkel E, Daigle G, Hussain U, Coye A, Rothstein J, Sareen D, Ornelas L, Banuelos M, Mandefro B, Ho R, Svendsen CN, Lim RG, Stocksdale J, Casale MS, Thompson TG, Wu J, Thompson LM, Dardov V, Venkatraman V, Matlock A, Van Eyk JE, Jaffe JD, Papanastasiou M, Subramanian A, Golub TR, Erickson SD, Fallahi-Sichani M, Hafner M, Gray NS, Lin JR, Mills CE, Muhlich JL, Niepel M, Shamu CE, Williams EH, Wrobel D, Sorger PK, Heiser LM, Gray JW, Korkola JE, Mills GB, LaBarge M, Feiler HS, Dane MA, Bucher E, Nederlof M, Sudar D, Gross S, Kilburn DF, Smith R, Devlin K, Margolis R, Derr L, Lee A, Pillai A.

Cell Syst. 2018 Jan 24;6(1):13-24. doi: 10.1016/j.cels.2017.11.001. Epub 2017 Nov 29. Review.

PMID:
29199020
5.

Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics.

Hafner M, Heiser LM, Williams EH, Niepel M, Wang NJ, Korkola JE, Gray JW, Sorger PK.

Sci Data. 2017 Nov 7;4:170166. doi: 10.1038/sdata.2017.166.

6.

Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW.

PLoS One. 2017 Oct 11;12(10):e0186551. doi: 10.1371/journal.pone.0186551. eCollection 2017.

7.

Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, Wood KW, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW.

Breast Cancer Res. 2017 Feb 9;19(1):17. doi: 10.1186/s13058-017-0809-6. No abstract available.

8.

Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling.

Hill SM, Nesser NK, Johnson-Camacho K, Jeffress M, Johnson A, Boniface C, Spencer SE, Lu Y, Heiser LM, Lawrence Y, Pande NT, Korkola JE, Gray JW, Mills GB, Mukherjee S, Spellman PT.

Cell Syst. 2017 Jan 25;4(1):73-83.e10. doi: 10.1016/j.cels.2016.11.013. Epub 2016 Dec 22.

9.

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.

Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ.

Oncotarget. 2016 Jun 28;7(26):40690-40703. doi: 10.18632/oncotarget.9816.

10.

Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, W Wood K, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW.

Breast Cancer Res. 2016 Jul 1;18(1):70. doi: 10.1186/s13058-016-0728-y. Erratum in: Breast Cancer Res. 2017 Feb 9;19(1):17.

11.

Mechanism and Role of SOX2 Repression in Seminoma: Relevance to Human Germline Specification.

Kushwaha R, Jagadish N, Kustagi M, Mendiratta G, Seandel M, Soni R, Korkola JE, Thodima V, Califano A, Bosl GJ, Chaganti RSK.

Stem Cell Reports. 2016 May 10;6(5):772-783. doi: 10.1016/j.stemcr.2016.04.002. Epub 2016 Apr 28.

12.

Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach.

Korkola JE, Heck S, Olshen AB, Feldman DR, Reuter VE, Houldsworth J, Bosl GJ, Chaganti RS.

PLoS One. 2015 Dec 1;10(12):e0142846. doi: 10.1371/journal.pone.0142846. eCollection 2015.

13.

Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.

Butler TM, Johnson-Camacho K, Peto M, Wang NJ, Macey TA, Korkola JE, Koppie TM, Corless CL, Gray JW, Spellman PT.

PLoS One. 2015 Aug 28;10(8):e0136407. doi: 10.1371/journal.pone.0136407. eCollection 2015.

14.

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

Korkola JE, Collisson EA, Heiser M, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW.

PLoS One. 2015 Jul 16;10(7):e0133219. doi: 10.1371/journal.pone.0133219. eCollection 2015. Erratum in: PLoS One. 2017 Oct 11;12 (10 ):e0186551.

15.

Erratum to: Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2015 May 12;16:95. doi: 10.1186/s13059-015-0658-5.

16.

Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency.

Kushwaha R, Jagadish N, Kustagi M, Tomishima MJ, Mendiratta G, Bansal M, Kim HR, Sumazin P, Alvarez MJ, Lefebvre C, Villagrasa-Gonzalez P, Viale A, Korkola JE, Houldsworth J, Feldman DR, Bosl GJ, Califano A, Chaganti RS.

Stem Cells. 2015 Feb;33(2):367-77. doi: 10.1002/stem.1870.

17.

Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2013;14(10):R110. Erratum in: Genome Biol. 2015;16:95.

18.

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ.

Breast Cancer Res Treat. 2012 Sep;135(2):505-17. doi: 10.1007/s10549-012-2188-0. Epub 2012 Aug 9.

19.

The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.

Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z.

Cancer Discov. 2012 Jul;2(7):638-51. doi: 10.1158/2159-8290.CD-12-0093. Epub 2012 May 10.

20.

A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.

Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M.

Cancer Discov. 2012 Aug;2(8):685-93. Epub 2012 May 24.

21.

Subtype and pathway specific responses to anticancer compounds in breast cancer.

Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9. doi: 10.1073/pnas.1018854108. Epub 2011 Oct 14.

22.

A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells.

Papapetrou EP, Korkola JE, Sadelain M.

Stem Cells. 2010 Feb;28(2):287-96. doi: 10.1002/stem.257.

23.

Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin.

Korkola JE, Houldsworth J, Bosl GJ, Chaganti RS.

BJU Int. 2009 Nov;104(9 Pt B):1334-8. doi: 10.1111/j.1464-410X.2009.08855.x. Review.

24.

Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors.

Korkola JE, Houldsworth J, Feldman DR, Olshen AB, Qin LX, Patil S, Reuter VE, Bosl GJ, Chaganti RS.

J Clin Oncol. 2009 Nov 1;27(31):5240-7. doi: 10.1200/JCO.2008.20.0386. Epub 2009 Sep 21.

25.

Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas.

Gopalan A, Dhall D, Olgac S, Fine SW, Korkola JE, Houldsworth J, Chaganti RS, Bosl GJ, Reuter VE, Tickoo SK.

Mod Pathol. 2009 Aug;22(8):1066-74. doi: 10.1038/modpathol.2009.66. Epub 2009 Apr 24.

26.

In vivo differentiation and genomic evolution in adult male germ cell tumors.

Korkola JE, Heck S, Olshen AB, Reuter VE, Bosl GJ, Houldsworth J, Chaganti RS.

Genes Chromosomes Cancer. 2008 Jan;47(1):43-55.

PMID:
17943972
27.

Identification of a robust gene signature that predicts breast cancer outcome in independent data sets.

Korkola JE, Blaveri E, DeVries S, Moore DH 2nd, Hwang ES, Chen YY, Estep AL, Chew KL, Jensen RH, Waldman FM.

BMC Cancer. 2007 Apr 11;7:61.

28.

Interferon-alpha resistance associated genes in renal cell carcinoma identified by expression profiling.

Korkola JE, Kondagunta GV, Reuter VE, Motzer RJ, Chaganti RS.

J Urol. 2007 Apr;177(4):1264-8; discussion 1268.

PMID:
17382702
29.

Biology and genetics of adult male germ cell tumors.

Houldsworth J, Korkola JE, Bosl GJ, Chaganti RS.

J Clin Oncol. 2006 Dec 10;24(35):5512-8.

PMID:
17158536
30.

Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells.

Chadalavada RS, Korkola JE, Houldsworth J, Olshen AB, Bosl GJ, Studer L, Chaganti RS.

Stem Cells. 2007 Mar;25(3):771-8. Epub 2006 Nov 30.

31.

Transcriptional program associated with IFN-alpha response of renal cell carcinoma.

Banerjee D, Chadalavada RS, Bourdon V, Korkola JE, Motzer RJ, Chaganti RS.

J Interferon Cytokine Res. 2006 Mar;26(3):156-70.

PMID:
16542138
32.

Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors.

Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS.

Cancer Res. 2006 Jan 15;66(2):820-7.

33.

Bladder cancer outcome and subtype classification by gene expression.

Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, Waldman FM.

Clin Cancer Res. 2005 Jun 1;11(11):4044-55.

34.

Gene expression-based classification of nonseminomatous male germ cell tumors.

Korkola JE, Houldsworth J, Dobrzynski D, Olshen AB, Reuter VE, Bosl GJ, Chaganti RS.

Oncogene. 2005 Jul 28;24(32):5101-7.

PMID:
15870693
35.

Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma.

Hwang ES, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, Esserman LJ, Waldman FM.

Cancer. 2004 Jun 15;100(12):2562-72.

36.

Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis.

Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM, Waldman FM.

Cancer Res. 2003 Nov 1;63(21):7167-75.

37.

Optimizing stringency for expression microarrays.

Korkola JE, Estep AL, Pejavar S, DeVries S, Jensen R, Waldman FM.

Biotechniques. 2003 Oct;35(4):828-35.

PMID:
14579749
38.

Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors.

Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, Carroll P, Kuo WL, Pinkel D, Albertson D, Cordon-Cardo C, Jain AN, Waldman FM.

Cancer Res. 2003 Jun 1;63(11):2872-80.

40.

Tissue-specific resistance to cancer development in the rat: phenotypes of tumor-modifier genes.

Wood GA, Korkola JE, Archer MC.

Carcinogenesis. 2002 Jan;23(1):1-9. Review.

PMID:
11756217
41.

Resistance of Copenhagen rats to hepatocarcinogenesis does not involve T-cell immunity.

Wood GA, Korkola JE, Archer MC.

Carcinogenesis. 2001 Feb;22(2):357-9.

PMID:
11181461
42.
43.
44.

Resistance of Copenhagen rats to chemical induction of glutathione S-transferase 7-7-positive liver foci.

Wood GA, Korkola JE, Lee VM, Sarma DS, Archer MC.

Carcinogenesis. 1997 Sep;18(9):1745-50.

PMID:
9328170

Supplemental Content

Loading ...
Support Center